Previous 10 | Next 10 |
China Finance Online (NASDAQ:JRJC) -43% after receiving Nasdaq delisting notice and announces private placement of ordinary shares and warrants Sesen Bio (NASDAQ:SESN) -36% after FDA declines to approve Sesen Bio's Vicineum bladder cancer treatment Standard Lithium (N...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. The S&P (SP500) and Dow (DJI) finished up for the second week in a row. The Nasdaq (COMP.IND) ended the week down as rates steadily gained from Monday ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Among the small cap companies making big moves today is PharmaCyte Biotech (OTCMKTS: PMCB ). Indeed, PMCB stock is up nearly 60% at the time of writing on very heavy volume. Source: Shutterstock Today’s p...
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced the closing of its previously anno...
PharmaCyte Biotech (OTCQB:PMCB) common stock expected to begin trading on Nasdaq on August 10, 2021, under the symbol “PMCB.” Company also announced the pricing of its previously announced underwritten public offering of ~3.53M shares. Each share of common stock is bei...
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced that the Company’s common s...
PharmaCyte Biotech, Inc. (OTCQB: PMCBD) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced that The Nasdaq Stock Market LLC (...
PharmaCyte Biotech, Inc. (OTCQB: PMCBD), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced that the production and shipping of test materials and stu...
PharmaCyte Biotech (PMCB) will effect a 1-for-1,500 reverse stock split of its common shares, leaving the company with only about 1.6M issued and outstanding shares from ~2.4B shares.Trading on reverse split-adjusted basis will commence at the opening of the market on July 12, 2021. “W...
PharmaCyte Biotech, Inc. (OTCQB: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced that it will effect a 1-for-1,500 r...
News, Short Squeeze, Breakout and More Instantly...
PharmaCyte Biotech Inc. Company Name:
PMCB Stock Symbol:
OTCMKTS Market:
PharmaCyte Biotech Inc. Website:
Second external investment in life sciences solidifies previously announced strategy to utilize significant cash position to create additional stockholder value PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”), today announced a $7 mi...